Q1 2025 Earnings Forecast for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Issued By Wedbush

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Analysts at Wedbush issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, May 7th. Wedbush analyst R. Driscoll expects that the company will earn ($0.72) per share for the quarter. Wedbush has a “Outperform” rating and a $52.00 price objective on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.26) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2028 earnings at $4.10 EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. During the same period in the prior year, the business earned ($0.49) earnings per share. The business’s quarterly revenue was down 100.0% compared to the same quarter last year.

A number of other equities analysts have also issued reports on the stock. Capital One Financial reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. BTIG Research initiated coverage on shares of IDEAYA Biosciences in a research note on Friday, March 8th. They set a “buy” rating and a $55.00 price objective on the stock. Leerink Partnrs restated an “outperform” rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. JPMorgan Chase & Co. increased their price target on IDEAYA Biosciences from $51.00 to $57.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Finally, The Goldman Sachs Group boosted their price objective on IDEAYA Biosciences from $36.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, January 25th. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, IDEAYA Biosciences currently has an average rating of “Buy” and a consensus target price of $47.50.

IDEAYA Biosciences Stock Performance

NASDAQ:IDYA opened at $40.64 on Thursday. IDEAYA Biosciences has a 1 year low of $20.68 and a 1 year high of $47.74. The business has a fifty day moving average of $42.57 and a 200-day moving average of $38.40. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -20.22 and a beta of 0.83.

Hedge Funds Weigh In On IDEAYA Biosciences

Institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. lifted its stake in IDEAYA Biosciences by 14.8% during the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock valued at $138,185,000 after buying an additional 500,046 shares in the last quarter. Walleye Capital LLC acquired a new position in IDEAYA Biosciences in the 3rd quarter worth approximately $2,265,000. Boone Capital Management LLC grew its position in IDEAYA Biosciences by 15.0% during the 3rd quarter. Boone Capital Management LLC now owns 570,682 shares of the company’s stock worth $15,397,000 after purchasing an additional 74,249 shares in the last quarter. Fisher Asset Management LLC raised its stake in IDEAYA Biosciences by 1,609.8% during the 4th quarter. Fisher Asset Management LLC now owns 539,025 shares of the company’s stock valued at $19,179,000 after purchasing an additional 507,500 shares during the period. Finally, Barclays PLC raised its stake in IDEAYA Biosciences by 17.8% during the 3rd quarter. Barclays PLC now owns 86,326 shares of the company’s stock valued at $2,330,000 after purchasing an additional 13,049 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.